肠道微生物群疗法治疗非酒精性脂肪性肝病：来自随机临床试验的证据。
Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials.
作者信息
Han Ting-Rui, Yang Wen-Juan, Tan Qing-Hua, Bai Shuai, Zhong Huang, Tai Yang, Tong Huan
机构信息
West China School of Medicine, Sichuan University, Chengdu, China.
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
出版信息
Front Microbiol. 2023 Jan 16;13:1004911. doi: 10.3389/fmicb.2022.1004911. eCollection 2022.
Abstract
Nonalcoholic fatty liver disease (NAFLD) has a high prevalence worldwide, but there are no medications approved for treatment. Gut microbiota would be a novel and promising therapeutic target based on the concept of the gut-liver axis in liver disease. We reviewed randomized controlled trials on gut microbiota therapy in NAFLD in this study to evaluate its efficacy and plausibility in NAFLD.
摘要
非酒精性脂肪性肝病（NAFLD）在全球范围内具有很高的患病率，但目前尚无获批用于治疗的药物。基于肝病中肠-肝轴的概念，肠道微生物群将是一个新颖且有前景的治疗靶点。在本研究中，我们回顾了关于NAFLD肠道微生物群疗法的随机对照试验，以评估其在NAFLD中的疗效和合理性。
相似文献
1
Gut microbiota therapy for nonalcoholic fatty liver disease: Evidence from randomized clinical trials.肠道微生物群疗法治疗非酒精性脂肪性肝病：来自随机临床试验的证据。
Front Microbiol. 2023 Jan 16;13:1004911. doi: 10.3389/fmicb.2022.1004911. eCollection 2022.
2
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群：非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
3
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.综述文章：细菌可以成为药物吗？益生菌和益生元作为非酒精性脂肪性肝病治疗手段的潜力。
Aliment Pharmacol Ther. 2019 Sep;50(6):628-639. doi: 10.1111/apt.15416. Epub 2019 Aug 2.
4
Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.调控非酒精性脂肪性肝病的肠道微生物组：益生菌、益生元、合生元和抗生素。
J Microbiol. 2018 Dec;56(12):855-867. doi: 10.1007/s12275-018-8346-2. Epub 2018 Oct 25.
5
New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease.肠道菌群与酒精性和非酒精性脂肪性肝病的新进展。
Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.
6
Fecal microbiota transplantation for treatment of non-alcoholic fatty liver disease: Mechanism, clinical evidence, and prospect.粪便微生物群移植治疗非酒精性脂肪性肝病：机制、临床证据与展望。
World J Gastroenterol. 2024 Feb 28;30(8):833-842. doi: 10.3748/wjg.v30.i8.833.
7
NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options.非酒精性脂肪性肝病/代谢功能障碍相关脂肪性肝病与肠-肝轴：从发病机制到治疗选择
Metabolites. 2024 Jun 28;14(7):366. doi: 10.3390/metabo14070366.
8
Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.肠道微生物群与非酒精性脂肪性肝病：机制与治疗的新视角。
Nutrients. 2017 Oct 16;9(10):1124. doi: 10.3390/nu9101124.
9
Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials.益生菌对非酒精性脂肪性肝病的影响：人体临床试验综述
Front Nutr. 2023 Jun 30;10:1155306. doi: 10.3389/fnut.2023.1155306. eCollection 2023.
10
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?非酒精性脂肪性肝病：调节肠道微生物群以改善严重程度？
Gastroenterology. 2020 May;158(7):1881-1898. doi: 10.1053/j.gastro.2020.01.049. Epub 2020 Feb 8.
引用本文的文献
1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.代谢功能障碍相关脂肪性肝病（MASLD）：肠道微生物群、胰岛素抵抗和糖尿病之间的相互作用
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
2
Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches.非酒精性脂肪性肝病中的种族和民族差异：利用表观遗传学和肠道微生物群途径制定靶向治疗方法。
Biomolecules. 2025 May 5;15(5):669. doi: 10.3390/biom15050669.
3
Importance of the gut microbiota in the gut-liver axis in normal and liver disease.肠道微生物群在正常及肝脏疾病状态下肠-肝轴中的重要性。
World J Hepatol. 2024 Jun 27;16(6):878-882. doi: 10.4254/wjh.v16.i6.878.
4
TCI711 Supplementation Improved Nonalcoholic Fatty Liver by Modulating Gut Microbiota: A Randomized, Placebo-Controlled, Clinical Trial.TCI711补充剂通过调节肠道微生物群改善非酒精性脂肪肝：一项随机、安慰剂对照临床试验
Curr Dev Nutr. 2024 Jan 19;8(3):102083. doi: 10.1016/j.cdnut.2024.102083. eCollection 2024 Mar.
5
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies.非酒精性脂肪性肝病与肠道微生物失调：潜在机制和肠道微生物介导的治疗策略。
Rev Endocr Metab Disord. 2023 Dec;24(6):1189-1204. doi: 10.1007/s11154-023-09843-z. Epub 2023 Oct 16.
6
Alanyl-Glutamine Dipeptide Attenuates Non-Alcoholic Fatty Liver Disease Induced by a High-Fat Diet in Mice by Improving Gut Microbiota Dysbiosis.丙氨酰-谷氨酰胺二肽通过改善肠道微生物失调减轻高脂饮食诱导的小鼠非酒精性脂肪肝疾病。
Nutrients. 2023 Sep 14;15(18):3988. doi: 10.3390/nu15183988.
7
Exercise Is Medicine for Nonalcoholic Fatty Liver Disease: Exploration of Putative Mechanisms.运动是治疗非酒精性脂肪肝的良药：潜在机制的探索。
Nutrients. 2023 May 24;15(11):2452. doi: 10.3390/nu15112452.
本文引用的文献
1
Current therapies and new developments in NASH.非酒精性脂肪性肝炎的当前治疗方法与新进展
Gut. 2022 Jun 16;71(10):2123-34. doi: 10.1136/gutjnl-2021-326874.
2
Nonalcoholic Fatty Liver Disease and the Gut-Liver Axis: Exploring an Undernutrition Perspective.非酒精性脂肪性肝病与肠-肝轴：从营养不良角度进行探索
Gastroenterology. 2022 Jun;162(7):1858-1875.e2. doi: 10.1053/j.gastro.2022.01.058. Epub 2022 Mar 3.
3
Biodiversity of Gut Microbiota: Impact of Various Host and Environmental Factors.肠道微生物组的多样性：各种宿主和环境因素的影响。
Biomed Res Int. 2021 May 12;2021:5575245. doi: 10.1155/2021/5575245. eCollection 2021.
4
Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial.益生菌和益生元补充对非酒精性脂肪性肝病代谢参数、肝转氨酶和全身炎症的影响：一项随机临床试验。
J Food Sci. 2020 Oct;85(10):3611-3617. doi: 10.1111/1750-3841.15367. Epub 2020 Sep 4.
5
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics.国际益生菌和益生元科学协会（ISAPP）关于共生元定义和范围的共识声明。
Nat Rev Gastroenterol Hepatol. 2020 Nov;17(11):687-701. doi: 10.1038/s41575-020-0344-2. Epub 2020 Aug 21.
6
Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial.异体粪菌移植治疗非酒精性脂肪性肝病患者改善异常小肠通透性：一项随机对照试验。
Am J Gastroenterol. 2020 Jul;115(7):1055-1065. doi: 10.14309/ajg.0000000000000661.
7
Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum.非酒精性脂肪性肝病-非酒精性脂肪性肝炎临床试验中饮食和运动的标准化：肝脏论坛的建议。
J Hepatol. 2020 Sep;73(3):680-693. doi: 10.1016/j.jhep.2020.04.030. Epub 2020 Apr 27.
8
Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD).随机双盲安慰剂对照试验研究菊粉联合甲硝唑治疗非酒精性脂肪性肝病（NAFLD）。
Nutrients. 2020 Mar 27;12(4):937. doi: 10.3390/nu12040937.
9
Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease.共生元改变粪便微生物组，但不能改变非酒精性脂肪性肝病患者的肝脏脂肪或纤维化：一项随机试验。
Gastroenterology. 2020 May;158(6):1597-1610.e7. doi: 10.1053/j.gastro.2020.01.031. Epub 2020 Jan 25.
10
The gut-liver axis in liver disease: Pathophysiological basis for therapy.肝脏疾病中的肠-肝轴：治疗的病理生理学基础。
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
Zotero 插件